Responses
Regular and young investigator award abstracts
Clinical trials completed
279 Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC impacts local-regional control and overall survival
Compose a Response to This Article
Other responses
No responses have been published for this article.
